China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug
30/06/2026 05:05
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug SHANGHAI, June 30 (Reuters) - Innovent Biologics 1801.HK has entered into an agreement that grants it sole commercialization rights for Eli Lilly's LLY.N breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tuesday.
Lilly will continue manufacturing, supplying and developing the drug, it said in a statement.
(Reporting by Andrew Silver in Shanghai; Editing by Christian Schmollinger)
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis